gip glp 1 dual agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica PDB-101: Molecule of the Month:

GLP-1 also affects non-hunger related (hedonic) feeding by targeting brain areas involved in reward, motivation and addiction, such as the VTA, NAcc, lateral septum [701,741,744,745], and PVT [704]

Semaglutide and Tirzepatide results can last a lifetime, but they require maintenance

Typically, weight loss is 37 kg at the doses used in type 2 diabetes, with semaglutide producing the greatest reduction (Nauck et al, 2021)

Drug Safe

doi: 10.1210/clinem/dgaa891 208 GierBButlerPCLaiCKKirakossianDDeNicolaMMYehMW

Contact your healthcare provider promptly if you experience: Persistent dizziness lasting more than a few seconds when standing Fainting or near-fainting episodes Falls or loss of balance attributed to dizziness Chest pain, palpitations, or irregular heartbeat accompanying low blood pressure symptoms Severe or persistent nausea, vomiting, or diarrhea leading to dehydration Confusion, difficulty concentrating, or unusual fatigue Blood pressure readings consistently below 90/60 mmHg with symptoms New or worsening shortness of breath Seek emergency care (call 911) if you experience: Loss of consciousness Chest pain or pressure Severe shortness of breath Confusion or altered mental status Seizures Signs of stroke (facial drooping, arm weakness, speech difficulty) Your healthcare provider may need to adjust your GLP-1 medication dose, modify or discontinue antihypertensive medications, or investigate other potential causes of hypotension